PRINCETON, N.J., March 28, 2011 /PRNewswire/ — Pharmasset, Inc.
VRUS) today announced that it will webcast an investor event
from the European Association for the Study of the Liver (EASL) on
Saturday, April 2, 2011 starting at 8:00pm CET. During this
webcast, management will review Pharmasset’s progress on the
programs that are the subject of presentations at EASL.
To access a simultaneous webcast of this event via the internet,
log on to the “Events & Presentations” section of the Investor
Center on Pharmasset’s website at http://investor.pharmasset.com/events.cfm.
Please connect to the website at least ten minutes prior to the
start of the presentation to ensure adequate time for a reliable
connection and any software download that may be necessary for the
“Once Daily PSI-7977 plus PegIFN/RBV: Rapid Virologic
Suppression in Treatment Naive Patients with HCV GT2/GT3 in a Phase
2b Trial” will be presented in the HCV Drug Development session on
Friday, April 1 at 4:15pm CET. Authors of the study are Lalezari,
J. et al.
“Once Daily PSI-7977 Plus Peg-IFN/RBV in HCV GT1: 98% Rapid
Virologic Response, Complete Early Virologic Response: The PROTON
Study” will be presented in a late breaker poster session on
Thursday, March 31. Authors of the study are Nelson, DR. et
“PSI-352938, A Novel Purine Nucleotide Analog, Exhibits Potent
Antiviral Activity and No Evidence of Resistance in Patients With
HCV Genotype 1 Over 7 Days” will be presented in a poster session
on Saturday, April 2. Authors of the study are Rodriguez-Torres M.
“Mechanism of HCV Replicon Resistance to PSI-352938, a Cy